JOHN KIRKWOOD to Head and Neck Neoplasms
This is a "connection" page, showing publications JOHN KIRKWOOD has written about Head and Neck Neoplasms.
Connection Strength
0.579
-
Building upon the standard of care in adjuvant therapy of high-risk melanoma. J Clin Oncol. 2005 Dec 01; 23(34):8559-63.
Score: 0.165
-
Integrated BATF transcriptional network regulates suppressive intratumoral regulatory T cells. Sci Immunol. 2023 09 15; 8(87):eadf6717.
Score: 0.142
-
Interferon-? Drives Treg Fragility to Promote Anti-tumor Immunity. Cell. 2017 Jun 01; 169(6):1130-1141.e11.
Score: 0.092
-
Age as a prognostic factor in patients with localized melanoma and regional metastases. Ann Surg Oncol. 2013 Nov; 20(12):3961-8.
Score: 0.070
-
Increased therapeutic index using moderate dose methotrexate and leucovorin twice weekly vs. weekly high dose methotrexate-leucovorin in patients with advanced squamous carcinoma of the head and neck: a safe new effective regimen. Cancer. 1981 May 15; 47(10):2414-21.
Score: 0.030
-
Resistance to PD1 blockade in the absence of metalloprotease-mediated LAG3 shedding. Sci Immunol. 2020 07 17; 5(49).
Score: 0.029
-
Phase II trial of interferon-alpha in locally recurrent or metastatic squamous cell carcinoma of the head and neck: immunological and clinical correlates. J Immunother Emphasis Tumor Immunol. 1996 Nov; 19(6):433-42.
Score: 0.022
-
Phase Ib trial of the effect of peritumoral and intranodal injections of interleukin-2 in patients with advanced squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group trial. J Immunother Emphasis Tumor Immunol. 1994 Feb; 15(2):134-9.
Score: 0.018
-
Interferons in the treatment of human cancer. J Clin Oncol. 1984 Apr; 2(4):336-52.
Score: 0.009